Key Takeaways
- Serina Therapeutics has secured a $15 million private placement funding, with a second tranche of up to $15 million expected soon.
- The financing includes warrant coverage, which could raise an additional $33.3 million, extending the company’s operational runway into 2027.
- Funds will support the company’s Phase 1b clinical trial for SER-252, targeting advanced Parkinson’s disease treatment.
Funding Announcement
Serina Therapeutics, Inc. announced a private placement deal that will raise $15 million in gross proceeds to fund its clinical trials, with a second tranche of up to $15 million anticipated by April 30, 2026. The funding is part of a strategy to enhance clinical development, specifically for the development of SER-252, a treatment for advanced Parkinson’s disease.
Details of the Financing
The shares are priced at $2.25 each, a 68% premium over the closing price on March 17, 2026. This funding package includes 50% warrant coverage priced at $5 per share, which could yield an additional $33.3 million if fully exercised. Greg Bailey, M.D., currently a Board Director, will assume the role of Co-Chairman, reflecting Serina’s commitment to strong leadership as it navigates this critical phase.
Clinical Trial Insights
The Phase 1b registrational study will assess SER-252’s safety, tolerability, and preliminary efficacy among patients with advanced Parkinson’s whose symptoms remain uncontrolled. Initial dosing has commenced at clinical sites in Australia, with further patient enrollment planned in the U.S. Results from the study’s initial cohort are expected to facilitate progress to the next stages by Q3 2026, aiming for topline results in the first half of 2027.
Leadership Perspective
Steve Ledger, Serina’s CEO, stated that this financing is crucial for achieving key milestones in the company’s history. He emphasized the alignment of financial resources with clinical progress. Dr. Bailey expressed his enthusiasm for Serina’s therapeutic technology and its potential to transform treatment options for the approximately 250,000 advanced Parkinson’s patients in the U.S. and Europe.
About Serina Therapeutics
Based in Huntsville, Alabama, Serina is focused on developing drugs to treat neurological conditions using its proprietary POZ Platform™, which optimizes drug delivery and efficacy. The company is actively exploring partnerships to expand the application of its technology.
Disclaimer
This announcement includes forward-looking statements that are subject to risks and uncertainties. Actual results may differ due to various factors, including clinical trial outcomes and regulatory approvals. It should not be considered an offer to sell or a solicitation of an offer to buy securities prior to compliance with registration requirements.
The content above is a summary. For more details, see the source article.